Resistance to carbapenem antibiotics, the last line of defence for many patients, is increasing globally.

In 2020, approximately 700 000 people will die from antibiotic resistant infections. By 2050, as many as 10 million deaths are forecast.

Zinc containing enzymes, the metallo-β-lactamases (MBL), are emerging as the most alarming resistance mechanisms.
Adjutec Pharma found the solution
metallo-β-lactamase resistance breaker APC148 which destroys vital bacterial carbapenem-resistance mechanisms (MBL) and prevents the bacteria from defending itself from the antibiotic.
Metallo-β-lactamase resistance breaker ZinChel which destroys vital bacterial carbapenem-resistance mechanisms (MBL)
APC148 is an innovative solution:
Comprehensive IP portfolio and pipeline
Carbapenem iv/oral adjuvant
Proprietary, water soluble molecule
Straightforward synthesis route
No APC148
resistance detected
APC148 is innovative solution:

Carbapenem iv/oral adjuvant

Proprietary, water soluble molecule

Straightforward synthesis route

Carbapenem iv/oral adjuvant

Proprietary, water soluble molecule

Development plans
Market opportunity
  • USD $62.06 Bn - size of the global antibiotic market by 2026 with the largest market in the North America and the fastest growing in Asia Pacific
  • EUR €26.5k - cost of antibiotic resistance per hospitalized patient in 2015
  • Key players identified in the carbapenem market are Pfizer and Sumitomo Dainippon Pharma
  • Adjutec Pharma AS competitive edge - no marketed, clinically available agents active against carbapenem-destroying MBLs available
Investment
  • Adjutec Pharma AS has received $ 3 million in grants including support from the Norwegian Research Council and Novo Nordisk
  • Adjutec Pharma AS was recently granted $ 1.8 million to run the preclinical program, and will raise another $ 22 million in investment to reach Phase II